Lingbo Biotech Announces ￥10M Series Pre-A Financing

(VCBeat) Apr. 24, 2021 -- After the angel round financing of ten million yuan led by TigerYeah Capital, Lingbo Biotechnology (Hangzhou) Co., Ltd. ("Lingbo Biotech") obtained the Pre-A round financing of tens of millions from Insight Capital in just a few months. According to this startup, this round of funding will be used for the preclinical research and development of new products for the company's bio-engineered artificial blood vessels.

Founded in 2019 and located in the medical port of Qiantang New District, Hangzhou, Lingbo Biotech is committed to the R&D of products that can replace and repair human tissues and organs based on tissue engineering and regenerative medicine. Lingbo Biotech aims to become the world's leading platform enterprise in the R&D and manufacturing of artificial organs and products for tissue repair.

According to Lingbo Biotech, the artificial blood vessel developed by the company is expected to break the barrier that traditional artificial blood vessels made either of collagen or a biodegradable polymer made of polymer cannot be small-caliber and regenerated. The self-developed artificial blood vessel is able to provide a safe and revolutionary artificial blood vessel product for patients who cannot be treated by traditional methods.

The first artificial blood vessel of Lingbo Biotech will be applied to the arteriovenous graft (AVG) surgery of hemodialysis patients. In the future, the product is expected to be extended to indications of other vascular diseases.

The biological blood vessels of Lingbo Biotech are currently the only type to bond the polymer materials to the acellular matrix. Polymer materials for vascular have excellent mechanical properties, while the acellular matrix has better biocompatibility, which makes it possible to produce endothelial artificial blood vessels. The corresponding technology may be applied to the future artificial esophagus, tissue repair, plastic surgery, and other fields.

Insight Capital is a venture capital firm focused on early-stage healthcare investment. It mainly invests in medical devices, medical services, new drug research and development, mobile health and other segments.

Founded in 2014, TigerYeah Capital is dedicated to build itself as a famous brand in the healthcare investment field and become a top-tier investment firm.  TigerYeah Capital focuses on early and growing equity investment in healthcare, especially in the field of the Medical Device, Health Food, CRO, and Health Services. By leveraging Tigermed solid platform and TigerYeah's abundant industrial resources, TigerYeah Capital provides comprehensive post-investment services for entrepreneurs.